NanoString Technologies, Inc. (NASDAQ:NSTG) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On October11, 2017, NanoString Technologies, Inc. (“NanoString” or the “Company”) issued a press release reporting certain preliminary financial results for the third quarter 2017. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNo. |
Description |
|
Press release dated October 11, 2017.
|
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
NanoString Technologies Inc ExhibitEX-99.1 2 nstgex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017SEATTLE – October 11,…To view the full exhibit click here
About NanoString Technologies, Inc. (NASDAQ:NSTG)
NanoString Technologies, Inc. develops and manufactures intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. It markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology, and to clinical laboratories and medical centers for diagnostic use. Its molecular diagnostic product Prosigna Breast Cancer Assay provides an assessment of a patient’s risk of recurrence for breast cancer.
